Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOT102 + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- SOTIO Biotech AG
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SOT102 + nab-paclitaxel + gemcitabine is a research-stage triple drug combination regimen. SOT102 is an investigational antibody-drug conjugate targeting Claudin18.2, under development for solid tumors, notably pancreatic cancer. Nab-paclitaxel (brand: Abraxane) is an albumin-bound formulation of paclitaxel that enables solvent-free intravenous delivery and improved tumor targeting. Gemcitabine (brand: Gemzar) is a nucleoside analog that inhibits DNA synthesis, widely used in pancreatic and other solid tumors. The combination is designed as an antineoplastic therapy, leveraging the cytotoxic actions of chemotherapy (nab-paclitaxel and gemcitabine) with the targeted effect of SOT102 to improve efficacy in pancreatic (and potentially other) cancers. Nab-paclitaxel + gemcitabine is approved for metastatic pancreatic cancer and has demonstrated improved survival compared to gemcitabine alone[2][3][4]. SOT102 is still in clinical development.
- Other names
- nab-paclitaxelpaclitaxel albumin-boundgemcitabine
02
Targets
Claudin 18.2TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on SOT102 + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SOT102 + nab-paclitaxel + gemcitabine.